Search JNJ
JOHNSON & JOHNSON
NYSE · CIK 200406
Last close256.03
Daily change-2.63 (-1.02%)
10 Years gain+151.49%
Dividends TTM5.28 (+3.94%)
Dividend yield2.04%
Fundamental Analysis
JNJ · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0103
Fundamental
56.1Momentum
n/aAcceleration
n/aConfidence
79.0Annual Revenue19
Quarterly Revenue82
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.9 / 25
Quality12.3 / 25
Capital Efficiency15.8 / 20
Balance Sheet7.9 / 15
Shareholder Economics9.3 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM10.11%OK
Revenue CAGR 3Y5.6%OK
Gross Margin67.99%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.67%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 28, 2025 | $94.19B | $63.94B | n/a | $24.53B | $19.70B | 67.88% | n/a | 20.91% | n/a | 2.43B |
| 2025 FY Dec 29, 2024 | $88.82B | $61.35B | n/a | $24.27B | $19.84B | 69.07% | n/a | 22.34% | n/a | 2.43B |
| 2025 FY Dec 31, 2023 | $85.16B | $58.61B | n/a | $22.79B | $18.25B | 68.82% | n/a | 21.43% | n/a | 2.56B |
| 2024 FY Jan 01, 2023 | $79.99B | $55.39B | n/a | $21.19B | $17.19B | 69.25% | n/a | 21.48% | n/a | 2.66B |
| 2023 FY Jan 02, 2022 | $78.74B | $55.34B | n/a | $23.41B | $19.76B | 70.28% | n/a | 25.09% | n/a | 2.67B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $97.11B | sum latest 4 fiscal quarters Revenue | OK | 0000200406-26-000153, 0000200406-25-000209 |
| Revenue Growth TTM | 10.11% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000200406-26-000153, 0000200406-25-000209 |
| Revenue CAGR 3Y | 5.6% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000200406-26-000016 |
| Revenue CAGR 5Y | 2.67% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000200406-26-000016 |
| Gross Profit CAGR 3Y | 4.9% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000200406-26-000016 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 67.99% | Gross Profit / Revenue | OK | 0000200406-26-000153, 0000200406-25-000209 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000200406-26-000153 |
| Current Ratio | 1.09x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.42x | (Cash + Short-term Investments) / Total Debt | OK | 0000200406-26-000153 |
| Revenue per Diluted Share | $39.80 | Revenue / Diluted Shares | OK | 0000200406-26-000153, 0000200406-25-000209 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0000200406-26-000016 |